{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:26:30Z","timestamp":1788909990018,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7\u201345.4) at \u226514 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3\u201384.5) at \u226514 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.<\/jats:p>","DOI":"10.1038\/s41467-022-32524-5","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T08:06:39Z","timestamp":1660377999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8077-8100","authenticated-orcid":false,"given":"Pilar T. V.","family":"Florentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-2270","authenticated-orcid":false,"given":"Fl\u00e1via J. O.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-2509","authenticated-orcid":false,"given":"Thiago","family":"Cerqueira-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-9650","authenticated-orcid":false,"given":"Vinicius de Ara\u00fajo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juracy B. S.","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelson G.","family":"Jantsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-536X","authenticated-orcid":false,"given":"Gerson O.","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Boaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-1436","authenticated-orcid":false,"given":"Guilherme L.","family":"Werneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-7903","authenticated-orcid":false,"given":"Manoel","family":"Barral-Netto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio L.","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-908X","authenticated-orcid":false,"given":"Enny S.","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"32524_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck","year":"2021","unstructured":"Frenck, R. W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 385, 239\u2013250 (2021).","journal-title":"N. Engl. J. Med."},{"key":"32524_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2116298","volume":"386","author":"EB Walter","year":"2022","unstructured":"Walter, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 386, 35\u201346 (2022).","journal-title":"N. Engl. J. Med."},{"key":"32524_CR3","unstructured":"Center for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). (2020). Available at: https:\/\/emergency.cdc.gov\/han\/2020\/han00432.asp. (Accessed: 14th May 2020)."},{"key":"32524_CR4","doi-asserted-by":"crossref","unstructured":"Stein, M. et al. Project Report The Burden of COVID-19 in children and its prevention by vaccination: a joint statement of the israeli pediatric association and the israeli society for pediatric infectious diseases. Vaccines 10, 81 (2022).","DOI":"10.3390\/vaccines10010081"},{"key":"32524_CR5","unstructured":"Minist\u00e9rio da Sa\u00fade do Brasil. Nota T\u00e9cnica No6\/2022-Secovid\/Gab\/Secovid\/Ms. (2022)."},{"key":"32524_CR6","doi-asserted-by":"crossref","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large- scale observational study. SSRN (2022).","DOI":"10.2139\/ssrn.4035405"},{"key":"32524_CR7","doi-asserted-by":"crossref","unstructured":"Jara, A. et al. Effectiveness of CoronaVac in children 3 to 5 years during the omicron SARS-CoV-2 outbreak. Nat. Med. 28, 1377\u20131380 (2022).","DOI":"10.1038\/s41591-022-01874-4"},{"key":"32524_CR8","doi-asserted-by":"crossref","unstructured":"Florentino, P. T. V. et al. Vaccine effectiveness of two-dose BNT162b2 over time against COVID-19 symptomatic infection and severe cases among adolescents: test negative design case control studies in Brazil and Scotland. The Lancet Infectious Diseases. 1\u201323 (2022).","DOI":"10.2139\/ssrn.4074678"},{"key":"32524_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"32524_CR10","doi-asserted-by":"crossref","unstructured":"Buchan, S. A., Nguyen, L., Wilson, S. E., Kitchen, S. A. & Kwong, J. Vaccine effectiveness of BNT162b2 against Omicron and Delta outcomes in adolescents. medRxiv 2022.04.07.22273319 (2022).","DOI":"10.1101\/2022.04.07.22273319"},{"key":"32524_CR11","first-page":"1","volume":"2","author":"L Veneti","year":"2022","unstructured":"Veneti, L. et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTtech) vaccine against reported SARS-CoV-2 delta and omicron infection among adolescents, Norway, August 2021 to January 2022. SSRN Electron. J. 2, 1\u201311 (2022).","journal-title":"SSRN Electron. J."},{"key":"32524_CR12","doi-asserted-by":"crossref","unstructured":"Dorabawila, V. et al. Effectiveness of the BNT162b2 vaccine among children 5\u201311 and 12\u201317 years in New York after the emergence of the Omicron Variant. medRxiv 2022.02.25.22271454 (2022).","DOI":"10.1101\/2022.02.25.22271454"},{"key":"32524_CR13","first-page":"1","volume":"2","author":"C Sacco","year":"2022","unstructured":"Sacco, C. et al. Articles Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5\u201311 years in Italy: a retrospective analysis of January-April, 2022. Lancet 2, 1\u20137 (2022).","journal-title":"Lancet"},{"key":"32524_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/EDE.0000000000001088","volume":"30","author":"J Vandenbroucke","year":"2019","unstructured":"Vandenbroucke, J. & Pearce, N. Test-negative designs differences and commonalities with other case\u2013control studies with \u201cother patient\u201d controls. Epidemiology 30, 838\u2013844 (2019).","journal-title":"Epidemiology"},{"key":"32524_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamapediatrics.2021.4217","volume":"176","author":"FS Dawood","year":"2022","unstructured":"Dawood, F. S., Porucznik, C. A., Veguilla, V. & Al, E. Incidence rates, household infection risk, and clinical characteristics of SARS-CoV-2 infection among children and adults in Utah and New York City, New York. Jama Pediatrics 176, 59\u201367 (2022).","journal-title":"Jama Pediatrics"},{"key":"32524_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2352-4642(22)00059-1","volume":"6","author":"AA Mensah","year":"2022","unstructured":"Mensah, A. A. et al. Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England. Lancet Child Adolesc. Health 6, 384\u2013392 (2022).","journal-title":"Lancet Child Adolesc. Health"},{"key":"32524_CR17","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1017\/S0950268819001961","volume":"147","author":"M Lipsitch","year":"2019","unstructured":"Lipsitch, M., Goldstein, E., Ray, G. T. & Fireman, B. Depletion-of-susceptibles bias in influenza vaccine waning studies: how to ensure robust results. Epidemiol. Infect. 147, e306 (2019).","journal-title":"Epidemiol. Infect."},{"key":"32524_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(21)02754-9","volume":"399","author":"SV Katikireddi","year":"2022","unstructured":"Katikireddi, S. V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet 399, 25\u201335 (2022).","journal-title":"Lancet"},{"key":"32524_CR19","doi-asserted-by":"crossref","unstructured":"Cerqueira-Silva, T. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. 28, 838\u2013843 (2022).","DOI":"10.1038\/s41591-022-01701-w"},{"key":"32524_CR20","doi-asserted-by":"crossref","unstructured":"Cerqueira-Silva, T. et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. Lancet Infect. Dis. 22, 1\u20132 (2022).","DOI":"10.1016\/S1473-3099(22)00288-2"},{"key":"32524_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1473-3099(22)00140-2","volume":"22","author":"T Cerqueira-Silva","year":"2022","unstructured":"Cerqueira-Silva, T. et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect. Dis. 22, 791\u2013801 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"32524_CR22","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1097\/EDE.0000000000001251","volume":"31","author":"JP Vandenbroucke","year":"2020","unstructured":"Vandenbroucke, J. P., Brickley, E. B., Vandenbroucke-Grauls, C. M. J. E. & Pearce, N. A test-negative design with additional population controls can be used to rapidly study causes of the SARS-COV-2 epidemic. Epidemiology 31, 836\u2013843 (2020).","journal-title":"Epidemiology"},{"key":"32524_CR23","unstructured":"Fiocruz. GISAID. Rede Gen\u00f4mica (2020). Available at: http:\/\/www.genomahcov.fiocruz.br\/#. (Accessed: 15th May 2022)"},{"key":"32524_CR24","doi-asserted-by":"crossref","unstructured":"Allik, M. et al. Small-area Deprivation Measure for Brazil: Data Documentation. University of Glasgow (2020). Available at: https:\/\/researchdata.gla.ac.uk\/980\/. (Accessed: 15th May 2020).","DOI":"10.36399\/gla.pubs.215898"},{"key":"32524_CR25","unstructured":"Vienna, A. R. Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; (2021)."},{"key":"32524_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al. Welcome to the Tidyverse Tidyverse package. J. Open Source Softw. 4, 1\u20136 (2019).","journal-title":"J. Open Source Softw."},{"key":"32524_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren, S. & Groothuis-Oudshoorn, K. mice: Multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1\u201367 (2011).","journal-title":"J. Stat. Softw."},{"key":"32524_CR28","first-page":"667","volume":"82","author":"D Firth","year":"1995","unstructured":"Firth, D. \u201cBias reduction of maximum likelihood estimates.\u201d. Biometrika 82, 667 (1995).","journal-title":"Biometrika"},{"key":"32524_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol, E. I. et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 12, 1\u201322 (2015).","journal-title":"PLoS Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32524-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32524-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32524-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:19:08Z","timestamp":1669295948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32524-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32524"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32524-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1604882\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B.-N. reports grants from the Fazer o bem faz bem program from JBS. S.A. V.dA.O., V.B., M.L.B., and M.B.-N. are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4756"}}